<DOC>
	<DOCNO>NCT01210053</DOCNO>
	<brief_summary>RATIONALE : Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . It yet know whether sunitinib effective treat non-small cell lung cancer . PURPOSE : This phase II trial study sunitinib see well work give maintenance therapy treat patient stage III stage IV non-small cell lung cancer previously treat combination chemotherapy .</brief_summary>
	<brief_title>Sunitinib Maintenance Therapy Treating Patients With Stage III Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To investigate effect sunitinib malate progression-free survival patient stage IIIB IV non-small cell lung cancer Secondary - To evaluate toxicity sunitinib administer maintenance setting . - To evaluate additional response rate sunitinib malate administer maintenance setting . - To evaluate overall survival patient treat sunitinib . After completion study treatment , patient follow every 2 month 1 year , every 6 month 1 year , periodically 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>No evidence symptomatic untreated brain metastasis , spinal cord compression , carcinomatous meningitis Histologically cytologically confirm primary nonsmall cell lung cancer stable respond disease prior treatment 36 course platinum base therapy Not candidate combined modality therapy No cavitary lesion Evidence symptomatic untreated brain metastasis , spinal cord compression , carcinomatous meningitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>